在长期使用新型 HMG-CoA 还原酶抑制剂匹伐他汀的治疗过程中，高密度脂蛋白胆固醇和载脂蛋白 A-I 持续升高。
High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor.
出版信息
Int J Cardiol. 2010 Jun 11;141(3):320-2. doi: 10.1016/j.ijcard.2008.11.130. Epub 2009 Jan 12.
Although a low level of high density lipoprotein-cholesterol (HDL-C) is an important risk factor for coronary heart disease, few available agents are capable of significantly increasing HDL-C. This multicenter study demonstrated that administration of pitavastatin, a new HMG-CoA reductase inhibitor, significantly and persistently increased HDL-C (from 36.0+/-5.9 to 40.5+/-9.1 mg/dL: p<0.001) and apolipoprotein A-I levels (from 108.4+/-18.0 to 118.7+/-19.3 mg/dL: p<0.01) in 43 hypercholesterolemic patients with low HDL-C over the course of 12 months of treatment. This suggests that pitavastatin may contribute to reduction in coronary heart disease.
虽然低水平的高密度脂蛋白胆固醇（HDL-C）是冠心病的一个重要危险因素，但目前可用的药物很少能显著增加 HDL-C。这项多中心研究表明，新型 HMG-CoA 还原酶抑制剂匹伐他汀可显著且持续地增加 HDL-C（从 36.0±5.9 至 40.5±9.1mg/dL：p<0.001）和载脂蛋白 A-I 水平（从 108.4±18.0 至 118.7±19.3mg/dL：p<0.01），在 43 例 HDL-C 水平低的高胆固醇血症患者中，治疗 12 个月后。这表明匹伐他汀可能有助于减少冠心病。
Zotero 插件